
NATURE . COM {
}
Title:
A phase II trial with rosiglitazone in liposarcoma patients | British Journal of Cancer
Description:
Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4 mg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2 – 16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Science
- Education
- Health & Fitness
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,058 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$63,100 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $42,042 to $115,617.
Keywords {🔍}
patients, liposarcoma, pparγ, treatment, pubmed, article, google, scholar, cancer, cas, nature, rosiglitazone, clinical, liposarcomas, human, expression, patient, gene, differentiation, molecular, peroxisome, proliferatoractivated, receptor, tumour, cells, study, months, cell, tontonoz, gamma, analysis, data, troglitazone, spiegelman, leuven, level, fletcher, cookies, content, trial, genes, biological, adipsin, protein, myxoid, fusion, activation, performed, probe, privacy,
Topics {✒️}
nature portfolio privacy policy peroxisome proliferator-activated receptor-γ peroxisome-proliferator activated receptor-gamma advertising nature 363 nature soft-tissue sarcoma—gold standard social media peroxisome proliferator-activated receptors author information authors 0/ reprints lipid-activated transcription factor pax8-ppargamma1 fusion oncogene author correspondence tls-chop fusion protein ews-chop fusion transcript ultrasound-guided needle biopsy full size image permissions myxoid/round cell subtypes inhibit tumour growth myxoid/round cell liposarcomas high affinity ligand soft tissue simulators privacy 14 october 2003 rna-binding protein primary tumour sample dei tos utilising standard procedures explore content tissue-specific regulator journals search log solid tumor differentiation human colon cancer metastastic colon cancer van den bh human myxoid liposarcoma round cell liposarcoma cellular proliferation rates european economic area personal data meis-kindblom giant marker chromosomes chromosomal region 12q spring-driven device quantify mrna levels glyceraldehyde-3-phosphate dehydrogenase g-banded chromosomes
Schema {🗺️}
WebPage:
mainEntity:
headline:A phase II trial with rosiglitazone in liposarcoma patients
description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
datePublished:2003-10-14T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1409
pageEnd:1412
sameAs:https://doi.org/10.1038/sj.bjc.6601306
keywords:
liposarcoma
rosiglitazone
PPARγ
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:A phase II trial with rosiglitazone in liposarcoma patients
description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
datePublished:2003-10-14T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1409
pageEnd:1412
sameAs:https://doi.org/10.1038/sj.bjc.6601306
keywords:
liposarcoma
rosiglitazone
PPARγ
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
External Links {🔗}(83)
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11751490 income
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Prognostic%20impact%20of%20p53%20status%2C%20TLS-CHOP%20fusion%20transcript%20structure%2C%20and%20histological%20grade%20in%20myxoid%20liposarcoma%3A%20a%20molecular%20and%20clinicopathologic%20study%20of%2082%20cases&journal=Clin%20Cancer%20Res&volume=7&pages=3977-3987&publication_year=2001&author=Antonescu%2CCR&author=Tschernyavsky%2CSJ&author=Decuseara%2CR&author=Leung%2CDH&author=Woodruff%2CJM&author=Brennan%2CMF&author=Bridge%2CJA&author=Neff%2CJR&author=Goldblum%2CJR&author=Ladanyi%2CM
- What's the financial intake of https://doi.org/10.1016%2FS0024-3205%2802%2901510-2?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12269390 rake in every month?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Apoptosis%20induced%20by%20activation%20of%20peroxisome-proliferator%20activated%20receptor-gamma%20is%20associated%20with%20Bcl-2%20and%20NF-kappaB%20in%20human%20colon%20cancer&journal=Life%20Sci&doi=10.1016%2FS0024-3205%2802%2901510-2&volume=70&pages=2631-2646&publication_year=2002&author=Chen%2CGG&author=Lee%2CJF&author=Wang%2CSH&author=Chan%2CUP&author=Ip%2CPC&author=Lau%2CWY?
- Discover the revenue of https://doi.org/10.1038%2F363640a0
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8510758's total income per month
- How much money does http://scholar.google.com/scholar_lookup?&title=Fusion%20of%20CHOP%20to%20a%20novel%20RNA-binding%20protein%20in%20human%20myxoid%20liposarcoma&journal=Nature&doi=10.1038%2F363640a0&volume=363&pages=640-644&publication_year=1993&author=Crozat%2CA&author=Aman%2CP&author=Mandahl%2CN&author=Ron%2CD make?
- How much profit does https://doi.org/10.1053%2Fadpa.2000.8133 generate?
- See how much http://scholar.google.com/scholar_lookup?&title=Liposarcoma%3A%20new%20entities%20and%20evolving%20concepts&journal=Ann%20Design%20Pathol&doi=10.1053%2Fadpa.2000.8133&volume=4&pages=252-266&publication_year=2000&author=Dei%20Tos%2CAP makes per month
- What's https://doi.org/10.1073%2Fpnas.96.7.3951's gross income?
- Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10097144
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22401's total income per month
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Induction%20of%20solid%20tumor%20differentiation%20by%20the%20peroxisome%20proliferator-activated%20receptor-gamma%20ligand%20troglitazone%20in%20patients%20with%20liposarcoma&journal=Proc%20Natl%20Acad%20Sci%20USA&doi=10.1073%2Fpnas.96.7.3951&volume=96&pages=3951-3956&publication_year=1999&author=Demetri%2CGD&author=Fletcher%2CCD&author=Mueller%2CE&author=Sarraf%2CP&author=Naujoks%2CR&author=Campbell%2CN&author=Spiegelman%2CBM&author=Singer%2CS
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10954962's earnings
- How much profit is http://scholar.google.com/scholar_lookup?&title=Rosiglitazone&journal=Int%20J%20Clin%20Pract&volume=54&pages=333-337&publication_year=2000&author=Goldstein%2CBJ making per month?
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11431375
- See how much http://scholar.google.com/scholar_lookup?&title=Mutational%20analysis%20of%20the%20peroxisome%20proliferator-activated%20receptor%20gamma%20gene%20in%20human%20malignancies&journal=Cancer%20Res&volume=61&pages=5307-5310&publication_year=2001&author=Ikezoe%2CT&author=Miller%2CCW&author=Kawano%2CS&author=Heaney%2CA&author=Williamson%2CEA&author=Hisatake%2CJ&author=Green%2CE&author=Hofmann%2CW&author=Taguchi%2CH&author=Koeffler%2CHP makes per month
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7805034's financial summary
- Get to know http://scholar.google.com/scholar_lookup?&title=Translocation%20t%2812%3B16%29%28q13%3Bp11%29%20in%20myxoid%20liposarcoma%20and%20round%20cell%20liposarcoma%3A%20molecular%20and%20cytogenetic%20analysis&journal=Cancer%20Res&volume=55&pages=24-27&publication_year=1995&author=Knight%2CJC&author=Renwick%2CPJ&author=Cin%2CPD&author=Van%20den%2CBH&author=Fletcher%2CCD's earnings
- What are the total earnings of https://doi.org/10.1126%2Fscience.289.5483.1357?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10958784 gross monthly?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=PAX8-PPARgamma1%20fusion%20oncogene%20in%20human%20thyroid%20carcinoma%20%5Bcorrected%5D&journal=Science&doi=10.1126%2Fscience.289.5483.1357&volume=289&pages=1357-1360&publication_year=2000&author=Kroll%2CTG&author=Sarraf%2CP&author=Pecciarini%2CL&author=Chen%2CCJ&author=Mueller%2CE&author=Spiegelman%2CBM&author=Fletcher%2CJA?
- What's the financial gain of https://doi.org/10.1097%2F00130404-200209000-00010?
- Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12416897
- Revenue of http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20troglitazone%2C%20an%20activator%20of%20the%20PPARgamma%20receptor%2C%20in%20patients%20with%20chemotherapy-resistant%20metastatic%20colorectal%20cancer&journal=Cancer%20J&doi=10.1097%2F00130404-200209000-00010&volume=8&pages=395-399&publication_year=2002&author=Kulke%2CMH&author=Demetri%2CGD&author=Sharpless%2CNE&author=Ryan%2CDP&author=Shivdasani%2CR&author=Clark%2CJS&author=Spiegelman%2CBM&author=Kim%2CH&author=Mayer%2CRJ&author=Fuchs%2CCS
- What's the monthly income of https://doi.org/10.1074%2Fjbc.270.22.12953?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7768881
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=An%20antidiabetic%20thiazolidinedione%20is%20a%20high%20affinity%20ligand%20for%20peroxisome%20proliferator-activated%20receptor%20gamma%20%28PPAR%20gamma%29&journal=J%20Biol%20Chem&doi=10.1074%2Fjbc.270.22.12953&volume=270&pages=12953-12956&publication_year=1995&author=Lehmann%2CJM&author=Moore%2CLB&author=Smith-Oliver%2CTA&author=Wilkison%2CWO&author=Willson%2CTM&author=Kliewer%2CSA?
- How much does https://link.springer.com/doi/10.1007/s004280100423 bring in each month?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11561754?
- Profit of http://scholar.google.com/scholar_lookup?&title=Cytogenetic%20and%20molecular%20genetic%20analyses%20of%20liposarcoma%20and%20its%20soft%20tissue%20simulators%3A%20recognition%20of%20new%20variants%20and%20differential%20diagnosis&journal=Virchows%20Arch&doi=10.1007%2Fs004280100423&volume=439&pages=141-151&publication_year=2001&author=Meis-Kindblom%2CJM&author=Sjogren%2CH&author=Kindblom%2CLG&author=Peydro-Mellquist%2CA&author=Roijer%2CE&author=Aman%2CP&author=Stenman%2CG
- How much does http://scholar.google.com/scholar_lookup?&title=ISCN.%20An%20International%20System%20for%20Human%20Genetic%20Nomenclature&publication_year=1995&author=Mitelman%2CF net monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11507074 rake in every month?
- How much money does http://scholar.google.com/scholar_lookup?&title=Anticancer%20effects%20of%20thiazolidinediones%20are%20independent%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20mediated%20by%20inhibition%20of%20translation%20initiation&journal=Cancer%20Res&volume=61&pages=6213-6218&publication_year=2001&author=Palakurthi%2CSS&author=Aktas%2CH&author=Grubissich%2CLM&author=Mortensen%2CRM&author=Halperin%2CJA generate?
- How much does https://doi.org/10.1172%2FJCI0215634 rake in every month?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12370270 income
- How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148 make?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=PPARgamma%20ligands%20inhibit%20primary%20tumor%20growth%20and%20metastasis%20by%20inhibiting%20angiogenesis&journal=J%20Clin%20Invest&doi=10.1172%2FJCI0215634&volume=110&pages=923-932&publication_year=2002&author=Panigrahy%2CD&author=Singer%2CS&author=Shen%2CLQ&author=Butterfield%2CCE&author=Freedman%2CDA&author=Chen%2CEJ&author=Moses%2CMA&author=Kilroy%2CS&author=Duensing%2CS&author=Fletcher%2CC&author=Fletcher%2CJA&author=Hlatky%2CL&author=Hahnfeldt%2CP&author=Folkman%2CJ&author=Kaipainen%2CA bring in?
- Financial intake of https://doi.org/10.1016%2FS1097-2765%2801%2980012-5
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10394368
- See how much http://scholar.google.com/scholar_lookup?&title=Loss-of-function%20mutations%20in%20PPAR%20gamma%20associated%20with%20human%20colon%20cancer&journal=Mol%20Cell&doi=10.1016%2FS1097-2765%2801%2980012-5&volume=3&pages=799-804&publication_year=1999&author=Sarraf%2CP&author=Mueller%2CE&author=Smith%2CWM&author=Wright%2CHM&author=Kum%2CJB&author=Aaltonen%2CLA&author=de%20la%2CCA&author=Spiegelman%2CBM&author=Eng%2CC makes per month
- Get to know what's the income of https://doi.org/10.1128%2FMCB.15.1.351
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7799943
- What's the monthly income of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC231968?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=PPAR%20gamma%202%20regulates%20adipose%20expression%20of%20the%20phosphoenolpyruvate%20carboxykinase%20gene&journal=Mol%20Cell%20Biol&doi=10.1128%2FMCB.15.1.351&volume=15&pages=351-357&publication_year=1995&author=Tontonoz%2CP&author=Hu%2CE&author=Devine%2CJ&author=Beale%2CEG&author=Spiegelman%2CBM?
- What's the monthly money flow for https://doi.org/10.1101%2Fgad.8.10.1224?
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7926726
- How much profit does http://scholar.google.com/scholar_lookup?&title=mPPAR%20gamma%202%3A%20tissue-specific%20regulator%20of%20an%20adipocyte%20enhancer&journal=Genes%20Dev&doi=10.1101%2Fgad.8.10.1224&volume=8&pages=1224-1234&publication_year=1994&author=Tontonoz%2CP&author=Hu%2CE&author=Graves%2CRA&author=Budavari%2CAI&author=Spiegelman%2CBM make?
- How much does https://doi.org/10.1016%2F0092-8674%2894%2990006-X bring in each month?
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8001151's earnings
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Stimulation%20of%20adipogenesis%20in%20fibroblasts%20by%20PPAR%20gamma%202%2C%20a%20lipid-activated%20transcription%20factor&journal=Cell&doi=10.1016%2F0092-8674%2894%2990006-X&volume=79&pages=1147-1156&publication_year=1994&author=Tontonoz%2CP&author=Hu%2CE&author=Spiegelman%2CBM?
- How much does https://doi.org/10.1073%2Fpnas.94.1.237 bring in each month?
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8990192
- Find out how much http://www.ncbi.nlm.nih.gov/pmc/articles/PMC19300 earns monthly
- What's http://scholar.google.com/scholar_lookup?&title=Terminal%20differentiation%20of%20human%20liposarcoma%20cells%20induced%20by%20ligands%20for%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20the%20retinoid%20X%20receptor&journal=Proc%20Natl%20Acad%20Sci%20USA&doi=10.1073%2Fpnas.94.1.237&volume=94&pages=237-241&publication_year=1997&author=Tontonoz%2CP&author=Singer%2CS&author=Forman%2CBM&author=Sarraf%2CP&author=Fletcher%2CJA&author=Fletcher%2CCD&author=Brun%2CRP&author=Mueller%2CE&author=Altiok%2CS&author=Oppenheim%2CH&author=Evans%2CRM&author=Spiegelman%2CBM's gross income?
- https://doi.org/10.1016%2FS0140-6736%2898%2910364-1's revenue stream
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10408502?
- http://scholar.google.com/scholar_lookup?&title=Medical%20significance%20of%20peroxisome%20proliferator-activated%20receptors&journal=Lancet&doi=10.1016%2FS0140-6736%2898%2910364-1&volume=354&pages=141-148&publication_year=1999&author=Vamecq%2CJ&author=Latruffe%2CN's financial summary
- How much profit is https://citation-needed.springer.com/v2/references/10.1038/sj.bjc.6601306?format=refman&flavour=references making per month?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=G%20Debrock?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22G%20Debrock%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=V%20Vanhentenrijk?
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22V%20Vanhentenrijk%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- How much income is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R%20Sciot earning monthly?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R%20Sciot%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- How much income does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Debiec-Rychter have?
- What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Debiec-Rychter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
- What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R%20Oyen?
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R%20Oyen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A%20Van%20Oosterom
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A%20Van%20Oosterom%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How profitable is https://s100.copyright.com/AppDispatchServlet?title=A%20phase%20II%20trial%20with%20rosiglitazone%20in%20liposarcoma%20patients&author=G%20Debrock%20et%20al&contentID=10.1038%2Fsj.bjc.6601306©right=The%20Author%28s%29&publication=0007-0920&publicationDate=2003-10-14&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-SA?
- How much money does https://citation-needed.springer.com/v2/references/10.1038/sj.bjc.6601306?format=refman&flavour=citation make?
- How much revenue does https://doi.org/10.1186/s12885-022-09379-6 generate?
- Learn about the earnings of https://doi.org/10.1186/s12944-021-01593-8
- Get to know what's the income of https://doi.org/10.1186/s12885-016-2524-6
- https://doi.org/10.1038/nrclinonc.2014.26's financial summary
- How much money does https://doi.org/10.1038/nrc3214 make?
- What is the monthly revenue of https://www.protocols.io/?
- How much income does https://www.natureindex.com/ have?
- What's the monthly income of http://www.naturechina.com?
- What is the earnings of https://www.natureasia.com/ja-jp?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref